SEC Form 4 · accession 0001671617-16-000002
Immune Therapeutics, Inc. · IMUN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clifford Selsky
Director
Period of report
Apr 8, 2016
Accepted (ET)
Apr 13, 2016 · 3:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001559356
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1,F2 | Apr 8, 2016 | J | 250,000 | $0.00 | A | 250,000 | I | Selsky Consulting, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were issued pursuant to a compensation agreement as a director of the company. The cost-basis is the market price on the day of issuance of $0.14
- F2The shares were issued directly to Selsky Consulting, LLC which is owned 100% by the reporting person.